## P I C O 및 근거표

| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
| :------------------------------------------ | :------------- | :------------------ | :----------------- | :-------------------- |
| 12 Quality of life- mastery score (CRQ) by eosinophil tertile | 1 | | WMD (Fixed, 95% CI) | 0.23 [0.03, 0.43] |
| 12.1 Lowest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 0.03 [-0.23, 0.29] |
| 12.2 Middle baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 0.2 [-0.20, 0.60] |
| 12.3 Highest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 0.82 [0.38, 1.26] |
| 13 Change in dyspnoea score | 1 | 92 | Mean Difference (IV, Fixed, 95% CI) | 0.2 [-0.15, 0.55] |
| 13.1 High dose oral steroid +ICS v ICS | 1 | 92 | Mean Difference (IV, Fixed, 95% CI) | 0.2 [-0.15, 0.55] |
| 14 Change in exertional dyspnoea score | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.20 [-1.02, 0.62] |
| 14.1 High dose oral steroid +ICS | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.20 [-1.02, 0.62] |
| 15 Symptom score- cough | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.3 [-0.82, 0.22] |
| 15.1 High dose oral steroid+ICS | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.3 [-0.82, 0.22] |
| 16 Symptom score- wheeze | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.30 [-1.21, 0.61] |
| 16.1 High dose oral steroid | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.30 [-1.21, 0.61] |
| 17 Symptom score- sputum | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.20 [-0.75, 0.35] |
| 17.1 High dose oral steroid | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.20 [-0.75, 0.35] |
| 18 Symptom score- activities of daily living | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.40 [-1.22, 0.42] |
| 18.1 High dose oral steroid | 1 | 42 | Mean Difference (IV, Fixed, 95% CI) | -0.40 [-1.22, 0.42] |
| 19 % decrease in symptom score: dyspnoea | 1 | | WMD (Fixed, 95% CI) | 9.51 [-4.14, 23.17] |
| 19.1 Lowest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 5.0 [-11.49, 21.49] |
| 19.2 Middle baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 14.0 [-15.09, 43.09] |
| 19.3 Highest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 32.0 [-12.61, 76.61] |
| 20 % decrease in symptom score: cough | 1 | | WMD (Fixed, 95% CI) | 21.08 [-21.04, 63. 20] |
| 20.1 Lowest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 2.0 [-54.21, 58.21] |
| 20.2 Middle baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 41.0 [-39.49, 121. 49] |
| 20.3 Highest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 53.0 [-50.76, 156. 76] |
| 21 % decrease in symptom score: wheeze | 1 | | WMD (Fixed, 95% CI) | 16.71 [4.04, 29.38] |
| 21.1 Lowest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | -1.0 [-28.15, 26.15] |
| 21.2 Middle baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 21.0 [6.45, 35.55] |
| 21.3 Highest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 42.0 [-40.43, 124. 43] |
| 22 % decrease in symptom score: sputum | 1 | | WMD (Fixed, 95% CI) | 22.84 [-5.71, 51.38] |
| 22.1 Lowest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 6.0 [-33.76, 45.76] |
| 22.2 Middle baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 34.0 [-31.94, 99.94] |
| 22.3 Highest baseline sputum eosinophil count | 1 | | WMD (Fixed, 95% CI) | 45.0 [-7.37, 97.37] |
| 23 >20% improvement in well-being (VAS) | 1 | | OR (Fixed, 95% CI) | 1.67 [0.71, 3.93] |
| 23.1 High dose oral steroid | 1 | | OR (Fixed, 95% CI) | 1.67 [0.71, 3.93] |
| 24 Functional capacity (Walking distance) | 3 | | SMD (Fixed, 95% CI) | 0.44 [0.14, 0.74] |
| 24.1 High dose oral steroid | 3 | | SMD (Fixed, 95% CI) | 0.44 [0.14, 0.74] |
| 25 Functional capacity (Shuttle walking distance) | 1 | | WMD (Fixed, 95% CI) | 12.67 [3.82, 21.52] |
| 25.1 LET | 1 | | WMD (Fixed, 95% CI) | 12.0 [-3.68, 27.68] |
| 25.2 MET | 1 | | WMD (Fixed, 95% CI) | 5.0 [-10.68, 20.68] |
| 25.3 HET | 1 | | WMD (Fixed, 95% CI) | 20.0 [5.30, 34.70] |
| 26 >20% improvement in 12 minute distance after treatment | 2 | | OR (Fixed, 95% CI) | 1.80 [1.22, 2.65] |
| 26.1 High dose oral steroid | 2 | | OR (Fixed, 95% CI) | 1.80 [1.22, 2.65] |
| 27 Peak expiratory flow | 3 | | WMD (Fixed, 95% CI) | 26.12 [7.05, 45.19] |
| 27.1 High dose oral steroid | 2 | | WMD (Fixed, 95% CI) | 27.37 [7.57, 47.17] |
| 27.2 High dose oral steroid+ICS | 1 | | WMD (Fixed, 95% CI) | 10.0 [-61.03, 81.03] |

<PAGE>126